Yonkosky D, Buffett R F, Bennett M
J Immunol. 1976 Jun;116(6):1695-703.
Mice were irradiated, infused with thymocytes and immunized with a variety of antigens, i.e., sheep or horse red blood cells (SRBC or HRBC), diphtheria toxoid (DT) or bovine gamma-globulin (BGG). The spleen cells (T.Spleen cells) were harvested 5 days later and cellfree extracts were prepared. The extracts contained an allogeneic suppressive factor (ASF) that was capable of inhibiting IgM antibody responses of allogeneic or semi-allogeneic unirradiated mice. ASF had to be injected within 24 hr of immunization to be effective and a single injection delayed, rather than abolished, the antibody response at the cellular level. However, daily injections of ASF resulted in persistent suppression of antibody response. ASF activity was antigen nonspecific, i.e., the antigen used to stimulate ASF production did not have to be the same as the antigen used to test for ASF activity. C3H T.Spleen extracts were even immunosuppressive when prepared by exposure to C3BF1 alloantigens only; such extracts suppressed antibody responses of C3BF1 and DBA/2 mice. C3H ASF was removed from extracts after incubation with C3BF1 spleen cells but not after incubation with C3H spleen cells. C3BF1 spleen cells which had been preincubated with C3H ASF were unable to generate antibody-forming cells upon transfer to irradiated C3BF1 host mice. This suggests that the ASF molecule may be or include receptors for alloantigens. The immunogenetic requirements for ASF activity were evaluated by injecting extracts from C3H, C57BL, C3BF and BALB/c T.Spleen cells into C3H, CBA, C57BL, BALB/c, DBA/2, A or C3H.A recipient mice. All extracts tested had ASF activity. However, all allogeneic recipients were not suppressed by the extract material. The suppressive activity of ASF seemed to require two (or more) antigenic differences between donors and recipients of extract material, an H-2K or I antigen difference and a second antigen difference, possibility Ig-1. In the limited numbers of strain combinations tested, T.Spleen extracts suppressed IgM antibody response only if exposed to H-2 and Ig-1 antigens, e.g., BALB/c (H-2d, Ig-1a) ASF suppressed A (H-2a, Ig-1e) but not C3H.A (H-2a, Ig-1a) or DBA/2 (H-2d, Ig-1c). Separate ASF molecules may react with separate antigens on the cell surface, i.e., with H-2 and gammaG2a. Alternatively, one ASF molecule may react with two structurally associated antigens. If the latter is correct, it is conceivable that the beta2-microglobulin which is non-covalently linked to the major component of H-2 molecules expresses allotypic antigens coded for by Ig-1 and beta2-microglobulin is one of the antigens recognized by ASF.
将小鼠进行辐照,注入胸腺细胞并用多种抗原进行免疫,即绵羊或马红细胞(SRBC或HRBC)、白喉类毒素(DT)或牛γ球蛋白(BGG)。5天后收获脾细胞(T.脾细胞)并制备无细胞提取物。提取物中含有一种同种异体抑制因子(ASF),它能够抑制同种异体或半同种异体未辐照小鼠的IgM抗体反应。ASF必须在免疫后24小时内注射才有效,单次注射虽会延迟但不会消除细胞水平的抗体反应。然而,每日注射ASF会导致抗体反应持续受到抑制。ASF活性是抗原非特异性的,即用于刺激ASF产生的抗原不必与用于检测ASF活性的抗原相同。仅通过暴露于C3BF1同种异体抗原制备的C3H T.脾提取物甚至具有免疫抑制作用;这种提取物抑制了C3BF1和DBA/2小鼠的抗体反应。C3H ASF与C3BF1脾细胞孵育后从提取物中去除,但与C3H脾细胞孵育后则不会。预先用C3H ASF孵育的C3BF1脾细胞转移到经辐照的C3BF1宿主小鼠后无法产生抗体形成细胞。这表明ASF分子可能是或包含同种异体抗原的受体。通过将C3H、C57BL、C3BF和BALB/c T.脾细胞的提取物注射到C3H、CBA、C57BL、BALB/c、DBA/2、A或C3H.A受体小鼠中来评估ASF活性的免疫遗传学要求。所有测试的提取物都具有ASF活性。然而,并非所有同种异体受体都被提取物抑制。ASF的抑制活性似乎需要提取物供体和受体之间存在两个(或更多)抗原差异,一个H - 2K或I抗原差异以及第二个抗原差异,可能是Ig - 1。在所测试的有限数量的品系组合中,T.脾提取物仅在暴露于H - 2和Ig - 1抗原时才抑制IgM抗体反应,例如BALB/c(H - 2d,Ig - 1a)ASF抑制A(H - 2a,Ig - 1e)但不抑制C3H.A(H - 2a,Ig - 1a)或DBA/2(H - 2d,Ig - 1c)。单独的ASF分子可能与细胞表面的不同抗原反应,即与H - 2和γG2a反应。或者,一个ASF分子可能与两个结构相关的抗原反应。如果后者正确,可以想象与H - 2分子主要成分非共价连接的β2 - 微球蛋白表达由Ig - 1编码的同种异型抗原,并且β2 - 微球蛋白是ASF识别的抗原之一。